[HTML][HTML] Nebulized versus dry powder long-acting muscarinic antagonist bronchodilators in patients with COPD and suboptimal peak inspiratory flow rate
DA Mahler, JA Ohar, CN Barnes, EJ Moran… - … Diseases: Journal of …, 2019 - ncbi.nlm.nih.gov
Background: Patients with chronic obstructive pulmonary disease (COPD) and suboptimal
peak inspiratory flow rate (sPIFR) may not benefit optimally from dry powder inhalers (DPI) …
peak inspiratory flow rate (sPIFR) may not benefit optimally from dry powder inhalers (DPI) …
Nebulized Versus Dry Powder Long-Acting Muscarinic Antagonist Bronchodilators in Patients With COPD and Suboptimal Peak Inspiratory Flow Rate
DA Mahler, JA Ohar, CN Barnes… - Chronic obstructive …, 2019 - pubmed.ncbi.nlm.nih.gov
Background Patients with chronic obstructive pulmonary disease (COPD) and suboptimal
peak inspiratory flow rate (sPIFR) may not benefit optimally from dry powder inhalers (DPI) …
peak inspiratory flow rate (sPIFR) may not benefit optimally from dry powder inhalers (DPI) …
Nebulized Versus Dry Powder Long-Acting Muscarinic Antagonist Bronchodilators in Patients With COPD and Suboptimal Peak Inspiratory Flow Rate.
DA Mahler, JA Ohar, CN Barnes, EJ Moran… - … Diseases (Miami, Fla …, 2019 - europepmc.org
Background: Patients with chronic obstructive pulmonary disease (COPD) and suboptimal
peak inspiratory flow rate (sPIFR) may not benefit optimally from dry powder inhalers (DPI) …
peak inspiratory flow rate (sPIFR) may not benefit optimally from dry powder inhalers (DPI) …
[PDF][PDF] Journal of the COPD Foundation Nebulized Versus Dry Powder Long-Acting Muscarinic Antagonist Bronchodilators in Patients With COPD and Suboptimal …
NVDP Long-Acting, IF Rate - researchgate.net
Background: Patients with chronic obstructive pulmonary disease (COPD) and suboptimal
peak inspiratory flow rate (sPIFR) may not benefit optimally from dry powder inhalers (DPI) …
peak inspiratory flow rate (sPIFR) may not benefit optimally from dry powder inhalers (DPI) …
[PDF][PDF] Journal of the COPD Foundation Nebulized Versus Dry Powder Long-Acting Muscarinic Antagonist Bronchodilators in Patients With COPD and Suboptimal …
NVDP Long-Acting, IF Rate - journal.copdfoundation.org
Background: Patients with chronic obstructive pulmonary disease (COPD) and suboptimal
peak inspiratory flow rate (sPIFR) may not benefit optimally from dry powder inhalers (DPI) …
peak inspiratory flow rate (sPIFR) may not benefit optimally from dry powder inhalers (DPI) …
[PDF][PDF] Journal of the COPD Foundation Nebulized Versus Dry Powder Long-Acting Muscarinic Antagonist Bronchodilators in Patients With COPD and Suboptimal …
NVDP Long-Acting, IF Rate - academia.edu
Background: Patients with chronic obstructive pulmonary disease (COPD) and suboptimal
peak inspiratory flow rate (sPIFR) may not benefit optimally from dry powder inhalers (DPI) …
peak inspiratory flow rate (sPIFR) may not benefit optimally from dry powder inhalers (DPI) …
Nebulized Versus Dry Powder Long-Acting Muscarinic Antagonist Bronchodilators in Patients With COPD and Suboptimal Peak Inspiratory Flow Rate.
DA Mahler, JA Ohar, CN Barnes, EJ Moran… - … Diseases (Miami, Fla …, 2019 - europepmc.org
Background: Patients with chronic obstructive pulmonary disease (COPD) and suboptimal
peak inspiratory flow rate (sPIFR) may not benefit optimally from dry powder inhalers (DPI) …
peak inspiratory flow rate (sPIFR) may not benefit optimally from dry powder inhalers (DPI) …